Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 2429Neoplasms 1840Carcinoma, Non-Small-Cell Lung 1615Prostatic Neoplasms 1309Colorectal Neoplasms 1147Lung Neoplasms 991Neoplasm Metastasis 836Multiple Myeloma 801Leukemia, Myeloid, Acute 777Ovarian Neoplasms 682Pancreatic Neoplasms 667Melanoma 667Squamous Cell Carcinoma of Head and Neck 592Recurrence 568Carcinoma, Hepatocellular 568Brain Neoplasms 529Glioblastoma 519Stomach Neoplasms 504Head and Neck Neoplasms 503Triple Negative Breast Neoplasms 472Lymphoma 462Uterine Cervical Neoplasms 454Carcinoma, Renal Cell 429Precursor Cell Lymphoblastic Leukemia-Lymphoma 419Lymphoma, Non-Hodgkin 392Endometrial Neoplasms 385Sarcoma 370Lymphoma, Follicular 358Urinary Bladder Neoplasms 356Lymphoma, Large B-Cell, Diffuse 355

Interventions

Radiotherapy 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Locally Advanced Unresectable Pancreatic Cancer Treated With Chemoradiotherapy × 1 year × Clear all
NCT02207465 2025-11-19

A Phase I Dual Dose Escalation Study of Radiation and Nab-Paclitaxel in Patients With Unresectable and Borderline Resectable Pancreatic Cancer

Abramson Cancer Center at Penn Medicine

Phase 1 Active not recruiting
42 enrolled
Gastrointestinal

Locally Advanced Unresectable Pancreatic Cancer Treated With Chemoradiotherapy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡